arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

MARAVAI LIFESCIENCES HOLDINGS, INC.

MRVI
$6.22 ▼ -0.04 (-0.56%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
7 Visible periods
31 Metrics
Peer-ranked Benchmarks
Price Chart
17
Health
Poor
Bearish
auto_awesome

Analytical Summary

MARAVAI LIFESCIENCES HOLDINGS, INC. faces fundamental challenges with weakness in Return on Common Equity (%) and Profit Margin (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $897.9M
Dividend Yield
Revenue Growth -28.3%
Op. Margin -115.9%
ROIC -41.9%
FCF / Share $-0.49
Trailing P/E
Price / Book 4.2x
FCF Yield
Debt / Equity 1.37
info Valuation on last close. End-of-day price, Aug 7, 2026.

7-Year Financial Trajectory

Annual
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$185.74M
↓ -28.3%
Net Income Profit after all expenses
$-130.77M
↑ +9.7%
Operating Margin Operating profit as % of sales
-115.9%
↓ -27.5% 2th
FCF / Share Free cash flow per share
$-0.49
↓ -204.4%
Long-Term Debt Long-term obligations
$291.77M
↓ -1.4%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Debt to EquityDebt to Equity is concerning (bottom quartile)
  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Profitability
4
Returns
14
Financial Health
26
Cash Quality
42

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 7 years · 25 quarters